i-SENS August Briefing – Reaping the rewards of long-term R&D investment

(August 19th, 2015) i-SENS is categorized as one of the best biotech companies in Korea. Within this category, the company has delivered a double-digit increase in operating profits – up by 14.8% from the same quarter last year. According to the article, the company says rewards from long-term investment in R&D are expected in near future.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *